Written description requirement

Seagen vs. Daiichi Sankyo: CAFC Opinion

December 4, 2025 by Patent2Profit

Seagen vs. Daiichi Sankyo marks a major setback for broad biologics genus claims as the Federal Circuit overturned Seagen’s $41.8M jury verdict, invalidating US10808039B2 for lack of written description and enablement under the post Amgen v. Sanofi standard.

Allergan vs. Sandoz – CAFC Strikes Down Allergan’s Latisse Patent Claim 30

November 21, 2025 by Patent2Profit

In the case of Allergan vs. Sandoz, the United States Court of Appeals for the Federal Circuit (CAFC) has invalidated a key Allergan patent covering the use of prostaglandin F (PGF) analogs for hair growth, handing a significant win to generic manufacturer Sandoz Inc.

⇧

Call Chat Email

We would love to hear from you! Get in touch with us for any queries, feedback, or collaboration opportunities.